Chilton Capital Management LLC Mi Nk Therapeutics, Inc. Transaction History
Chilton Capital Management LLC
- $2.19 Billion
- Q2 2024
A detailed history of Chilton Capital Management LLC transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Chilton Capital Management LLC holds 309 shares of INKT stock, worth $225. This represents 0.0% of its overall portfolio holdings.
Number of Shares
309
Previous 309
-0.0%
Holding current value
$225
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding INKT
# of Institutions
34Shares Held
912KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA234KShares$170,9520.0% of portfolio
-
Longbow Finance Sa Lutry, V8167KShares$121,6660.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny128KShares$93,3230.0% of portfolio
-
Geode Capital Management, LLC Boston, MA96.3KShares$70,3330.0% of portfolio
-
Black Rock Inc. New York, NY87.2KShares$63,6530.0% of portfolio
About MiNK Therapeutics, Inc.
- Ticker INKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,775,100
- Market Cap $24.7M
- Description
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...